SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the Phase 3 APPROACH topline readout for HLP003 in major depressive disorder, a closely watched binary catalyst. Traders are hopeful the results will validate the drugs potential, while others emphasize the risk of disappointing data and debate dilution, execution, and competition in the psychedelic-treatment sector.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Attention centers on Praxiss Investor Day and the approaching FDA decisions for relutrigine and ulixacaltamide, alongside expected EMERALD trial data and launch preparations. Many traders are bullish on the pipeline and commercial opportunity, while others stress that the regulatory outcomes and launch potential remain uncertain.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and subsequent bounce have sparked a debate over whether oversold conditions and support mark a near-term bottom or whether bearish momentum points to further losses. Traders speculate that liquidations, ETF outflows, and broader risk-off concerns are adding pressure, but no single cause dominates the discussion.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,699,860,951.91490568 with 589,238,106,731,035.4551592 in circulation. The last known price of Shiba Inu is 0.00000379 USD and is down -10.85 over the last 24 hours. It is currently trading on 1128 active market(s) with $78,538,817.41 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid frustration over its prolonged weakness and lack of momentum, with traders citing its large token supply, limited utility, and fading meme-coin hype. Views are split between holders accumulating dips and hoping for a revival, and skeptics expecting further declines; repeated chart commentary describes consolidation with a bearish tilt.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop following an air-traffic-control communications outage has put Delta in focus, with continuing delays and cancellations raising concerns about operational and earnings impacts. Traders disagree on whether the disruption is a temporary setback or a larger risk, while speculation about its cause remains unverified.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention ahead of its quarterly results, with traders focused on whether sales and guidance can hold up as housing and renovation demand remain soft. Some see the recent share-price strength as momentum into earnings, while skeptics point to weaker customer traffic, growth driven more by larger purchases, and sensitivity to high rates.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Positive interim REGAIN data in recurrent glioblastoma presented at SNO is driving attention, with traders reacting enthusiastically to the early responses and looking to the investor call for detail on durability, safety, and the path to a larger dataset. Some caution that the results are still early and debate whether the excitement is already reflected in the share price.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00312867 USD and is down -5.82 over the last 24 hours. It is currently trading on 374 active market(s) with $10,034,947.48 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMY is drawing attention amid persistent weakness and volatile price action, with traders debating whether the decline reflects broader crypto-market pressure or concerns about the projects execution and Haras focus on Janction (JCT). Some holders are buying the dip and citing ecosystem development, while skeptics call the token abandoned or accuse the team of favoring Janction.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Reports of an AstraZeneca acquisition proposal and speculation about a competing bidder are driving attention, with traders debating whether another offer could improve the terms. Some expect a deal, while others stress that the reported proposal is nonbinding and no transaction has been confirmed.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers quarterly results are drawing attention after revenue and adjusted earnings beat expectations and the company raised its revenue outlook, while lower EPS guidance tied to licensing charges has tempered the reaction. Traders are weighing the stronger sales and growth portfolio against deal-related costs and longer-term patent-expiration concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


InvestingSince2021

CB, Structural Biologist